We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 24 Jun 2021
Image: VITROS® Automation Solutions (Photo courtesy of Ortho Clinical Diagnostics)
Image: VITROS® Automation Solutions (Photo courtesy of Ortho Clinical Diagnostics)
Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its wide range of VITROS diagnostic testing and automation solutions at MEDLAB Middle East 2021.

Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.

Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.

Related Links:
Ortho Clinical Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Automatic CLIA Analyzer
Shine i6000

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more